Journey Medical Corporation (DERM) is a commercial-stage pharmaceutical company headquartered in Scottsdale, Arizona, that acquires, licenses, develops and markets FDA-approved prescription dermatology products through a specialty sales force. Its portfolio pairs the fast-growing oral rosacea treatment Emrosi with legacy brands such as Qbrexza, Accutane, Amzeeam and Targadox.
In the opening minutes of the November 18 session, DERM shares traded at $3.84, a decline of 1.54% from the prior session's close of $3.90. The direction is unambiguously lower, though the magnitude is modest relative to the stock's recent behavior. No verified news catalyst was identified for the move; the price action is best understood as continued digestion of a disappointing third-quarter report and a pair of analyst estimate resets.
No verified news or fundamental catalyst found explains today's decline. No press release, SEC filing, contract win, clinical update, or financing announcement was published before or during the session. The move is therefore best assessed as technical and flow-driven in a stock with a very thin order book.
The pattern is consistent with speculative micro-cap trading rather than institutional repositioning. The stock has averaged roughly 114,000 shares per session over the past three months, yet traded only a few thousand shares in the first minutes of November 18, so even small orders can shift the quoted price by several percent. Intraday, the shares have already oscillated between roughly $3.65 and $3.90 — a range wider than the net change — which is characteristic of gaps between bids in a low-liquidity name rather than a directional repricing on information.
The dominant influence on sentiment remains the third-quarter report published November 12. Journey Medical reported revenue of $19.0 million, up 8% year over year, but below consensus expectations in the $20 million to $22 million range. GAAP net loss narrowed to $1.3 million, or $0.05 per share, yet that also fell short of the small profit analysts had modeled. Emrosi net sales reached $9.0 million, an 84% year-over-year increase, and adjusted EBITDA of $3.5 million was positive for a second straight quarter.
What unsettled investors was forward visibility. Management declined to provide formal 2027 guidance, citing uncertainty over patient mix and the timing of formulary wins. The company also disclosed that a change to its co-pay bridging program, from $0.35 to $0.50, disrupted prescription trends from late September into October. For a company with a roughly $108 million market capitalization, that combination of a revenue miss and a guidance vacuum is material, and the shares have fallen in three of the four sessions since.
Two research notes trimmed price targets while retaining Buy ratings. On November 13, B. Riley lowered its target to $13 from $15, pointing to softer Emrosi net pricing as new formulary wins had yet to convert into reimbursed volume, while noting strong prescriber growth and expanding margins. On November 16, Alliance Global cut its target to $12 from $14, citing October prescription "noise" but describing the long-term Emrosi trend as promising. H.C. Wainwright reiterated a Buy rating and a $13 target.
Even after the reductions, published targets sit several times above the current share price, which helps explain why the stock bounced 5.41% on November 17 following a 14.5% slide a day earlier. Today's pullback fits that pattern of violent, two-way swings rather than a fresh fundamental judgment.
Volume is running well below the stock's recent pace. After sessions of roughly 318,000 and 245,000 shares on November 16 and 17, turnover on November 18 opened at a fraction of the three-month average near 114,000 shares. The light tape argues against attributing the decline to institutional distribution.
Technically, the shares remain in a pronounced downtrend. DERM closed at $3.90 on November 17, well beneath a 50-day moving average of about $5.73, and the November 16 session printed a 52-week low of $3.40. The stock is down roughly 21% over the past month and about 49% over the past year. No support level was broken today; the shares are consolidating just above that multi-month floor. The move was idiosyncratic rather than sector-driven, with no identifiable macro release or healthcare-wide catalyst behind it.
The score runs on a 0-to-100 scale, where 0 means no meaningful news and a price move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, rare move.
For Journey Medical, the verified news backdrop is weak: the earnings miss and analyst target cuts are now several sessions old and were already absorbed by the market, and nothing new was published today. The price move was equally unremarkable — at 1.54%, it was less than half the stock's average absolute daily move of about 3.3% over the past 60 sessions, and 38 of those 60 sessions produced equal or larger swings. The combination of stale, moderate news and a routine move yields a score of 6 out of 100.
Attention now shifts to fourth-quarter results, expected in February or March 2027, and to the trajectory of Emrosi prescriptions. Management has said it expects October's disruption to normalize over four to eight weeks, with December historically a strong month, so monthly prescription data will be scrutinized before the next report.
The key structural catalyst is the addition of Emrosi to the formulary of the largest national health plan in the United States, covering more than 25 million lives, effective January 2027. That shift could lift average selling prices and gross-to-net as prescriptions migrate from the co-pay bridging program into reimbursed claims, though first-quarter deductible resets may delay the benefit. Risks include continued erosion of legacy brands facing generic competition, the $22.3 million cash balance against ongoing spending, and the absence of formal 2027 guidance. Investors should treat the current $3.84 level as a sentiment reading on those variables, not as a resolved valuation.
Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the list rotates as conditions change. Reviewing it regularly can help traders see which approaches are working now and where to focus next.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 232 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 84 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for DERM turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 41 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for DERM moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.929) is normal, around the industry mean (6.379). P/E Ratio (-20.318) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric